Toward a Functional Definition of a “Rare Disease” for Regulatory Authorities and Funding Agencies

Haffner, 1991, Orphan products: origins, progress, and prospects, Annu Rev Pharmacol Toxicol, 31, 603, 10.1146/annurev.pa.31.040191.003131 Haffner, 2002, Orphan drug product regulation--United States. Int J, Clin Pharmacol Ther, 40, 84, 10.5414/CPP40084 Orphan Drug Act, Pub L. No. 97-414, Sect. J(b), 21 USC Sect. 360aa, note 551 (1983). Haffner, 2006, Adopting orphan drugs—two dozen years of treating rare diseases, N Engl J Med, 354, 445, 10.1056/NEJMp058317 Denis, 2010, Issues surrounding orphan diseases and orphan drug policies in Europe, Appl Health Econ Health Policy, 8, 343, 10.2165/11536990-000000000-00000 Fehr, 2006, Drug development for neglected diseases: a public health challenge, Tropical Med Int Health, 11, 1335, 10.1111/j.1365-3156.2006.01714.x Laupacis, 1992, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations, CMAJ, 146, 473 Drummond, 2007, Assessing the economic challenges posed by orphan drugs, Int J Technol Assess Health Care, 23, 36, 10.1017/S0266462307051550 Cheung, 2004, Orphan drug policies: implications for the United States, Canada and developing countries, Health Law J, 12, 83 Hernberg-Ståhl, 2013 Lehmann, 2014, Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes, J Pathol, 232, 142, 10.1002/path.4280 Clark, 1995, Diagnosis and classification of psychopathology: challenges to the current system and future directions, Ann Rev Psychol, 46, 121, 10.1146/annurev.ps.46.020195.001005 Young, 1982, A clinical and genetic study of Hunter’s syndrome, 2: differences between the mild and severe forms, J Med Genet, 19, 408, 10.1136/jmg.19.6.408 Young, 1982, Mild form of Hunter’s syndrome: clinical delineation based on 31 cases, Arch Dis Child, 57, 828, 10.1136/adc.57.11.828 Valenzano, 2011, Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders, Assay Drug Dev Technol, 9, 213, 10.1089/adt.2011.0370 Winquist, 2012, An evaluation framework for funding drugs for rare diseases, Value Health, 15, 982, 10.1016/j.jval.2012.06.009 Winquist, 2014, Application of a policy framework for the public funding of drugs for rare diseases, J Gen Int Med, 29, 774, 10.1007/s11606-014-2885-y Schiffmann, 2013, Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa, Genet Med, 15, 983, 10.1038/gim.2013.56 Kishnani, 2006, A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease, J Pediatr, 148, 671, 10.1016/j.jpeds.2005.11.033 Desnick, 2001, α-Galactosidase A deficiency: Fabry disease Meikle, 1999, Prevalence of lysosomal storage disorders, JAMA, 281, 249, 10.1001/jama.281.3.249 Spada, 2006, High incidence of later-onset Fabry disease revealed by newborn screening, Am J Hum Genet, 79, 31, 10.1086/504601 Hwu, 2009, Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A), Hum Mutat, 30, 1397, 10.1002/humu.21074 Muller, 1992, Power calculations for general linear multivariate models including repeated measures applications, J Am Stat Assoc, 87, 1209, 10.1080/01621459.1992.10476281 Guo, 2013, Selecting a sample size for studies with repeated measures, BMC Med Res Method, 13, 100, 10.1186/1471-2288-13-100 Clarke, 2001, Managing public payment for high-cost/high-benefit treatment: enzyme replacement therapy of Gaucher disease in Ontario, CMAJ, 165, 595 Sirrs, 2010, Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative, Mol Genet Metab, 99, 367, 10.1016/j.ymgme.2009.11.001 Sirrs, 2014, Outcomes of patients treated through the Canadian Fabry Disease Initiative, Mol Genet Metab, 111, 499, 10.1016/j.ymgme.2014.01.014 Connock, 2006, The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review, Health Technol Assess, 10, iii Institute of Medicine. Strengthening a workforce for innovative regulatory science in therapeutics development. Workshop summary, 2011. Available from: http://www.ncbi.nlm.nih.gov/books/NBK92889/?report=reader. [Accessed July 2, 2014]. 2010